P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT

類似資料

• Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma
  著者:: François Volery, 等
  出版事項: (2024-09-01)
• Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland
  著者:: Tomasz J. Ślebioda, 等
  出版事項: (2022-11-01)
• CAR T-Cell therapy for the management of mantle cell lymphoma
  著者:: Zoufang Huang, 等
  出版事項: (2023-03-01)
• Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis
  著者:: Nico Gagelmann, 等
  出版事項: (2026-05-01)
• Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease
  著者:: Erin A. Dean, MD, 等
  出版事項: (2023-03-01)